



Emerging Challenges in Primary Care

Update 2017

91% of Attendees are Engaged in Direct Patient Care

Knowledge

Competence

Confidence

Performance

New Agents, New Options, and Expanded Potential In Lipid Management: Integrating The Data Into Practice

FINAL LIVE OUTCOMES REPORT

LEARNING OBJECTIVES:

- 1 Employ evidence based treatment strategies for primary and secondary prevention of cardiovascular disease in high-risk patient populations
- 2 Discuss ACC recommendations on the role of non-statin therapies in the management of atherosclerotic cardiovascular disease
- 3 Explain the role of anti-PCSK9 monoclonal antibody therapy in LDL-C reduction to achieve cardiovascular risk reduction
- 4 List 2017 Quality Measures for the use of statin therapy for the prevention and treatment of cardiovascular disease

#	Learning Objective (N = 1670)	Pre-Test (SD)	Post-Test (SD)	% Change	P Value
1	Employ evidence based treatment strategies for primary and secondary prevention of cardiovascular disease in high-risk patient populations	48.97% (28.06)	58.57% (28.96)	19.60*	<.0001
2	Discuss ACC recommendations on the role of non-statin therapies in the management of atherosclerotic cardiovascular disease	51.89% (26.09)	68.07% (23.41)	31.18*	<.0001
3	Explain the role of anti-PCSK9 monoclonal antibody therapy in LDL-C reduction to achieve cardiovascular risk reduction	51.81% (30.32)	74.16% (28.43)	43.14*	<.0001
4	List 2017 Quality Measures for the use of statin therapy for the prevention and treatment of cardiovascular disease	34.14% (53.06)	52.96% (50.63)	55.13*	<.0001

- ◆ Learners understand current guidelines for the use of non-statin therapy, and which ones are effective
- ◆ Participants are significantly more aware of the role of anti-PCSK9 monoclonal antibody therapy and the evidence supporting primary and secondary prevention of cardiovascular disease
- ◆ Significantly increased awareness of 2017 Quality measures for statin therapy
- ◆ 38% improvement in managing hypercholesterolemia in patients with ASCVD

Sanofi US and Regeneron Grant ID 10754

Statistically significant gains were measured across the curriculum from Pre-Test to Post-Test in all learning domains across the intervention

The findings reveal that this education has the potential to impact **1,581,552** patients on an annual basis.


2,852 Total Attendees

11 Cities


1,909 On Site

943 Remote Simulcast


Number of Providers in Your Practice



Number of Patients Seen Each Week



Learning Domain Performance



Outcome Indicator (N = 1294)	Knowledge	Competence	RealIndex	Confidence
Pre-Test	15%	53.8%	57.7%	2.76
Post-Test	41%	67.21%	79.53%	3.68
% Change (Significance)	173.33 (p<.05)	24.93 (p<.05)	37.83 (p<.05)	33.33 (p<.05)

